Vical Incorporated (VICL) Release: Vaxfectin® Enhances Preclinical Immune Responses to Baxter's Cell Culture-Derived Influenza Vaccines
5/6/2013 9:42:44 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
SAN DIEGO, May 6, 2013 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced the online publication1 of Baxter's (Baxter International Inc.) (NYSE:BAX) preclinical evaluations of Vical's Vaxfectin® adjuvant in combination with Baxter's cell culture-derived seasonal and pandemic influenza vaccines. Simple addition of Vaxfectin® to the influenza vaccines substantially increased both antibody and T-cell responses compared with nonadjuvanted vaccines in mice and guinea pigs.
Help employers find you! Check out all the jobs and post your resume.
comments powered by